Modified Oligonucleotides for PLP1 RNA Suppression in PMD
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There are no effective treatments for leukodystrophies such as Pelizaeus-Merzbacher disease (PMD), a severe and fatal childhood disorder caused by PLP1 misfolding and overexpression, leading to dysmyelination and various symptoms including hypotonia, nystagmus, respiratory distress, and seizures.
Innovation Solution
Development of compounds, particularly modified oligonucleotides, to reduce the amount or activity of PLP1 RNA and protein, targeting specific sequences in the PLP1 gene to ameliorate symptoms of leukodystrophies like PMD.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If palliative care is provided, then quality of life is maintained, but disease progression cannot be halted
Solution Approach 1:
The patent extracts and removes the harmful PLP1 protein from the system using antisense oligonucleotides that bind to PLP1 mRNA, preventing its translation. This directly addresses the root cause of the disease by removing the toxic gain-of-function protein rather than merely managing symptoms
Solution Approach 2:
The patent introduces antisense oligonucleotides as intermediary molecules that mediate between the PLP1 mRNA and the harmful PLP1 protein. These oligonucleotides bind to the mRNA and prevent protein synthesis, acting as a molecular mediator to block the disease mechanism
2Object-affected harmful factors
If PLP1 expression is reduced, then toxic gain-of-function is ameliorated, but normal myelination may be affected
Solution Approach 1:
The patent applies local quality by using modified oligonucleotides with specific chemical modifications (such as phosphorothioate backbones and 2'-O-methoxyethyl ribose) that enhance binding specificity to PLP1 mRNA. This localized chemical modification allows selective targeting of the toxic PLP1 isoform while preserving normal myelination functions
Solution Approach 2:
The patent changes the chemical parameters of the oligonucleotide molecules by introducing various modifications (phosphorothioate linkages, 2'-O-methoxyethyl groups, bicyclic nucleosides) that alter binding affinity, stability, and specificity. These parameter changes enable selective reduction of PLP1 toxicity while maintaining therapeutic safety
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compounds effectively decrease PLP1 expression, alleviating symptoms such as hypotonia, nystagmus, respiratory distress, and seizures, providing a potential therapeutic benefit for PMD patients.
Implementation Method 1
The modified oligonucleotide is capable of hybridizing with a PLP1 nucleic acid
Data Source
AI summary
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of PLP1 RNA in a cell or subject, and in certain instances reducing the amount of proteolipid protein 1 in a cell or subject. Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a leukodystrophy. Such symptoms and hallmarks include hypotonia, nystagmus, optic atrophy, respiratory distress, motor delays, cognitive dysfunction, speech dysfunction, spasticity, ataxia, seizures, choreiform movements, and death. Such leukodystrophies include Pelizaeus-Merzbacher disease.